Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Maccura Biotechnology Co. Ltd. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 actions are handled by 3 distinct examiners, but they are concentrated within 2 distinct art units. This distribution means that every pending action is being reviewed by a different examiner, requiring the company to adapt to 3 different individual styles. WILDER, CYNTHIA B is the busiest examiner for the company, with 1 pending office action.
The fact that 3 distinct examiners are working within only 2 distinct art units suggests some overlap in the administrative oversight of the portfolio. Practitioners should be prepared for the 3 distinct examiners to potentially share resources or perspectives common to the 2 distinct art units, even as they manage the 3 pending office actions independently. Navigating 3 pending office actions across 2 distinct art units requires a coordinated approach that respects the individual examiner's discretion while accounting for the shared environment of the units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILDER, CYNTHIA B | 1 | 71.0% | +26.6% |
| BERTAGNA, ANGELA MARIE | 1 | 44.7% | +46.3% |
| CHIU, MAY LEUNG | 1 | 44.8% | +24.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639010 | SAMPLE ADDING NEEDLE FOR PREPARING MICRODROPLETS AND MICRODROPLET PREPARATION METHOD | CHIU, MAY LEUNG | 17d overdue |
| 18027971 | MULTIPLEX NUCLEIC ACID DETECTION METHOD, COMPOSITION AND KIT | BERTAGNA, ANGELA MARIE | 21d |
| 18724405 | PRIMER PROBE FOR DETECTION, PRIMER PROBE SET, AND APPLICATION THEREOF | WILDER, CYNTHIA B | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18724405 | PRIMER PROBE FOR DETECTION, PRIMER PROBE SET, AND APPLICATION THEREOF | WILDER, CYNTHIA B | — | §112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18027971 | MULTIPLEX NUCLEIC ACID DETECTION METHOD, COMPOSITION AND KIT | BERTAGNA, ANGELA MARIE | 1681 | §112 | Final Rejection | 21d | Pending | Mar 23, 2023 |
| 17639010 | SAMPLE ADDING NEEDLE FOR PREPARING MICRODROPLETS AND MICRODROPLET PREPARATION METHOD | CHIU, MAY LEUNG | 1758 | §103 | Final Rejection | 17d overdue | Pending | Feb 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial